Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Paul Nghiem

Fred Hutchinson Cancer Center

Intervention

Avelumab(drug)

Enrollment

50 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2028

Study locations (30)

• UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
• UC San Diego Moores Cancer Center, La Jolla, California, United States
• Keck Medicine of USC Koreatown, Los Angeles, California, United States
• Los Angeles General Medical Center, Los Angeles, California, United States
• USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
• USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
• UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
• Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
• UCHealth University of Colorado Hospital, Aurora, Colorado, United States
• Yale University, New Haven, Connecticut, United States
• Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
• UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
• University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cutaneous neuroendocrine carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07302347
  A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE2NCT07288073
  TIL Therapy in cSCC and MCC
  Karam Khaddour, MD, MS
• RECRUITINGNCT07215988
  Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
  Ohio State University Comprehensive Cancer Center
• RECRUITINGPHASE1NCT06940440
  IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
  TuHURA Biosciences, Inc.
• RECRUITINGPHASE2, PHASE3NCT06947928
  Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
  TuHURA Biosciences, Inc.
• RECRUITINGNCT06780475
  Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGPHASE1NCT07080242
  Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
  SystImmune Inc.
• RECRUITINGNCT06608511
  Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
  University of Wisconsin, Madison

See all trials for Cutaneous neuroendocrine carcinoma →